Start With EYLEA. Stay With EYLEA.1

TRUST 8 YEARS OF EXTENSIVE CLINICAL EXPERIENCE AND THE INTEGRITY OF DATA FROM LARGE, WELL–CONTROLLED CLINICAL TRIALS1

EYLEA is the #1 prescribed anti–VEGF FDA approved for Wet AMD, DME, and MEfRVO*

*IBM Truven MarketScan data: Number of injections administered from Q4 2017 through Q3 2018; data on file.

The Established Experience of EYLEA1,2

8 years of real–world experience1

An estimated 9 million doses administered to ≈790,000 eyes since launch (and counting)2

8 phase 3 clinical trials including more than 3000 EYLEA–treated patients across all approved indications: Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (MEfRVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR)1

Dosing Flexibility in Wet AMD: EYLEA Offers 3 FDA-Approved Dosing Intervals1

EYLEA 2 mg (0.05 mL) Dosing Schedule1

Wet AMD Initial Dosing Follow-Up Dosing Options
2 mg every 4 weeks
x 3 injections
2 mg every 8 weeks
2 mg every 4 weeks
After one year of effective therapy: 2 mg every 12 weeks
EYLEA dosing for Wet AMD. Initial dosing 2 mg every 4 weeks x 3 injections. Follow-up dosing options of either 2 mg every 8 weeks or 2 mg every 4 weeks. After one year of effective therapy 2 mg every 12 weeks.

Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every–4–week (monthly) dosing after the first 12 weeks (3 months).

Although not as effective as the recommended every–8–week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly.

ONLY EYLEA IS APPROVED TO TREAT 4 RETINAL CONDITIONS
WITH ONE SINGLE-DOSE-STRENGTH PRE-FILLED SYRINGE (PFS)1

IN STOCK AND AVAILABLE FOR ORDERING

The PFS offers a more convenient way to prepare EYLEA for administration when compared to vials1:

  • Fewer components to handle
  • Helps eliminate multiple preparation steps

One dosage strength may help:

  • Simplify ordering and billing
  • Streamline inventory management

Preparation of the single-dose, pre-filled syringe for intravitreal administration

Support for the reimbursement process.
Reimbursement Support

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details
Product support for EYLEA® (aflibercept) Injection.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works
EYLEA news, events, and more.
Resources

Get the information you
and your patients need
about EYLEA.

See resources
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. August 2019.
  2. Data on file. Regeneron Pharmaceuticals, Inc.